Frédéric Stauffer

2.2k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Frédéric Stauffer is a scholar working on Molecular Biology, Organic Chemistry and Genetics. According to data from OpenAlex, Frédéric Stauffer has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 8 papers in Organic Chemistry and 3 papers in Genetics. Recurrent topics in Frédéric Stauffer's work include PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer-related gene regulation (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). Frédéric Stauffer is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer-related gene regulation (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). Frédéric Stauffer collaborates with scholars based in Switzerland, United States and China. Frédéric Stauffer's co-authors include Sauveur-Michel Maira, Christian Schnell, Pascal Furet, Carlos García-Echeverría, Christine Fritsch, Alain De Pover, Patrick Chêne, Josef Brueggen, Marjo Simonen and William R. Sellers and has published in prestigious journals such as Angewandte Chemie International Edition, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Frédéric Stauffer

22 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

2008 954 citations Sauveur-Michel Maira, Frédéric Stauffer et al. Molecular Cancer Therapeutics profile →

Peers

Frédéric Stauffer

ONCOL

GENET

PFM

Nathan T. Ihle United States

Josef Brueggen Switzerland

Jessica Adickes United States

Kenna Anderes United States

Jay Gibbons United States

Christine Fritsch Switzerland

Matthew R. Janes United States

Michael Zinda United States

Katherine G. Moss United States

Jung-Sik Kim United States

Nathan T. Ihle United States

Frédéric Stauffer

1.2k ×0.9

352 ×1.0

ONCOL

216 ×0.9

GENET

213 ×0.9

PFM

184 ×0.8

Citations per year, relative to Frédéric Stauffer Frédéric Stauffer (= 1×) peers Nathan T. Ihle

Countries citing papers authored by Frédéric Stauffer

Since Specialization

Citations

This map shows the geographic impact of Frédéric Stauffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Stauffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Stauffer more than expected).

Fields of papers citing papers by Frédéric Stauffer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Stauffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Stauffer. The network helps show where Frédéric Stauffer may publish in the future.

Co-authorship network of co-authors of Frédéric Stauffer

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Stauffer. A scholar is included among the top collaborators of Frédéric Stauffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Stauffer. Frédéric Stauffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weiss, Andreas, Frédéric Stauffer, Henrik Möbitz, et al.. (2020). Abstract 1770: A new DOT1L inhibitor with in vivo activity in mouse models of MLL-translocated leukemia. Cancer Research. 80(16_Supplement). 1770–1770.

Stauffer, Frédéric, Andreas Weiss, Clemens Scheufler, et al.. (2019). New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse. ACS Medicinal Chemistry Letters. 10(12). 1655–1660. 27 indexed citations

Möbitz, Henrik, Rainer Machauer, Philipp Holzer, et al.. (2017). Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach. ACS Medicinal Chemistry Letters. 8(3). 338–343. 42 indexed citations

Chen, Chao, Hugh Zhu, Frédéric Stauffer, et al.. (2016). Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach. ACS Medicinal Chemistry Letters. 7(8). 735–740. 51 indexed citations

Fairhurst, Robin A., Thomas H. Marsilje, Stefan Stutz, et al.. (2016). Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(8). 2057–2064. 7 indexed citations

Hoegenauer, Klemens, Nicolas Soldermann, Frédéric Stauffer, et al.. (2016). Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. ACS Medicinal Chemistry Letters. 7(8). 762–767. 49 indexed citations

Stauffer, Frédéric, Sandra W. Cowan‐Jacob, Clemens Scheufler, & Pascal Furet. (2016). Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(8). 2065–2067. 15 indexed citations

Scheufler, Clemens, Henrik Möbitz, Christoph Gaul, et al.. (2016). Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket. ACS Medicinal Chemistry Letters. 7(8). 730–734. 37 indexed citations

Jahnke, Wolfgang, Guido Bold, Andreas L. Marzinzik, et al.. (2015). A General Strategy for Targeting Drugs to Bone. Angewandte Chemie International Edition. 54(48). 14575–14579. 22 indexed citations

10.

Jahnke, Wolfgang, Guido Bold, Andreas L. Marzinzik, et al.. (2015). Gezielte Anreicherung von Wirkstoffen am Knochen am Beispiel von allosterischen FPPS‐Inhibitoren. Angewandte Chemie. 127(48). 14783–14787. 2 indexed citations

11.

Marzinzik, Andreas L., René Amstutz, Guido Bold, et al.. (2015). Discovery of Novel Allosteric Non‐Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding. ChemMedChem. 10(11). 1884–1891. 24 indexed citations

12.

Stauffer, Frédéric, Pascal Furet, Andreas Floersheimer, & Marc Lang. (2012). New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series. Bioorganic & Medicinal Chemistry Letters. 22(5). 1860–1863. 11 indexed citations

13.

Marone, Romina, Thomas Bohnacker, Christian Schnell, et al.. (2009). Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. Molecular Cancer Research. 7(4). 601–613. 92 indexed citations

14.

Maira, Sauveur-Michel, Pascal Furet, & Frédéric Stauffer. (2009). Discovery of Novel Anticancer Therapeutics Targeting the Pi3K/Akt/Mtor Pathway. Future Medicinal Chemistry. 1(1). 137–155. 24 indexed citations

15.

Schnell, Christian, Frédéric Stauffer, Peter R. Allegrini, et al.. (2008). Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging. Cancer Research. 68(16). 6598–6607. 143 indexed citations

16.

Maira, Sauveur-Michel, Frédéric Stauffer, Josef Brueggen, et al.. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics. 7(7). 1851–1863. 954 indexed citations breakdown →

17.

Stauffer, Frédéric, Sauveur-Michel Maira, Pascal Furet, & Carlos Garcı́a-Echeverrı́a. (2008). Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorganic & Medicinal Chemistry Letters. 18(3). 1027–1030. 73 indexed citations

18.

Stauffer, Frédéric, Carlos Garcı́a-Echeverrı́a, Pascal Furet, et al.. (2007). Medicinal chemistry efforts towards the identification and development of inhibitors of phosphatidylinositol 3-kinases (PI3Ks) and related protein kinases for cancer treatment. Cancer Research. 67. 3953–3953. 2 indexed citations

19.

Parrish, Jay P., David B. Kastrinsky, Frédéric Stauffer, et al.. (2003). Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065. Bioorganic & Medicinal Chemistry. 11(17). 3815–3838. 30 indexed citations

20.

Boger, Dale L., Frédéric Stauffer, & Michael P. Hedrick. (2001). Substituent effects within the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065. Bioorganic & Medicinal Chemistry Letters. 11(15). 2021–2024. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact